These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6690074)

  • 1. Physicochemical characteristics of ferric adriamycin complexes.
    Bachur NR; Friedman RD; Hollenbeck RG
    Cancer Chemother Pharmacol; 1984; 12(1):5-9. PubMed ID: 6690074
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron(III)-adriamycin and Iron(III)-daunorubicin complexes: physicochemical characteristics, interaction with DNA, and antitumor activity.
    Beraldo H; Garnier-Suillerot A; Tosi L; Lavelle F
    Biochemistry; 1985 Jan; 24(2):284-9. PubMed ID: 2983753
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early clinical trial with quelamycin.
    Cortés-Funes H; Gosálvez M; Moyano A; Mañas A; Mendiola C
    Cancer Treat Rep; 1979 May; 63(5):903-8. PubMed ID: 455331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyl radical production and DNA damage induced by anthracycline-iron complex.
    Muindi JR; Sinha BK; Gianni L; Myers CE
    FEBS Lett; 1984 Jul; 172(2):226-30. PubMed ID: 6086388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical characterization and thermodynamic stability assessment of a colloidal iron drug product: iron sucrose.
    Shah RB; Yang Y; Khan MA; Raw A; Yu LX; Faustino PJ
    Int J Pharm; 2014 Apr; 464(1-2):46-52. PubMed ID: 24440404
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fine-granular cationic iron colloid. Its preparation, physicochemical characteristics and histochemical use for the detection of ionized anionic groups.
    Seno S; Akita M; Ono T; Tsujii T
    Histochemistry; 1985; 82(4):307-12. PubMed ID: 2409058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adriamycin and its iron(III) and copper(II) complexes. Glutathione-induced dissociation; cytochrome c oxidase inactivation and protection; binding to cardiolipin.
    Hasinoff BB; Davey JP
    Biochem Pharmacol; 1988 Oct; 37(19):3663-9. PubMed ID: 2845993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Time-dependent modifications of ferric-adriamycin.
    Gelvan D; Berg E; Saltman P; Samuni A
    Biochem Pharmacol; 1990 Apr; 39(8):1289-95. PubMed ID: 2157447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adriamycin-iron catalysed phospholipid peroxidation: a reaction not involving reduced adriamycin or hydroxyl radicals.
    Gutteridge JM
    Biochem Pharmacol; 1983 Jun; 32(12):1949-52. PubMed ID: 6309187
    [No Abstract]   [Full Text] [Related]  

  • 10. Binding of adriamycin-Fe3+ complex to membrane phospholipids.
    Demant EJ
    Eur J Biochem; 1984 Aug; 142(3):571-5. PubMed ID: 6468379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reappraisal of the association between adriamycin and iron.
    Gelvan D; Samuni A
    Cancer Res; 1988 Oct; 48(20):5645-9. PubMed ID: 3167821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oxidative destruction of DNA by the adriamycin-iron complex.
    Eliot H; Gianni L; Myers C
    Biochemistry; 1984 Feb; 23(5):928-36. PubMed ID: 6324858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The iron(III) and copper(II) complexes of adriamycin promote the hydrolysis of the cardioprotective agent ICRF-187 ((+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane).
    Hasinoff BB
    Agents Actions; 1990 Mar; 29(3-4):374-81. PubMed ID: 2160191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The iron(III)-adriamycin complex inhibits cytochrome c oxidase before its inactivation.
    Hasinoff BB; Davey JP
    Biochem J; 1988 Mar; 250(3):827-34. PubMed ID: 2839147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ferric chloride flocculation for nonflocculating beef extract preparations.
    Payment P; Fortin S; Trudel M
    Appl Environ Microbiol; 1984 Mar; 47(3):591-2. PubMed ID: 6324679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chromoxane cyanine R. I. Physical and chemical properties of the dye and of some of its iron complexes.
    Kiernan JA
    J Microsc; 1984 Apr; 134(Pt 1):13-23. PubMed ID: 6201615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thermodynamic stability assessment of a colloidal iron drug product: sodium ferric gluconate.
    Yang Y; Shah RB; Faustino PJ; Raw A; Yu LX; Khan MA
    J Pharm Sci; 2010 Jan; 99(1):142-53. PubMed ID: 19492341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction of the cardioprotective agent ICRF-187 [+)-1,2-bis(3,5-dioxopiperazinyl-1-yL)propane); its hydrolysis product (ICRF-198); and other chelating agents with the Fe(III) and Cu(II) complexes of adriamycin.
    Hasinoff BB
    Agents Actions; 1989 Mar; 26(3-4):378-85. PubMed ID: 2544086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quelamycin, a new derivative of adriamycin with several possible therapeutic advantages.
    Gosálvez M; Blanco MF; Vivero C; Vallés F
    Eur J Cancer (1965); 1978 Nov; 14(11):1185-90. PubMed ID: 216553
    [No Abstract]   [Full Text] [Related]  

  • 20. Removal of Coxsackie and bacterial viruses in water by flocculation. I. Removal of Coxsackie and bacterial viruses in water of known chemical content by flocculation with aluminum sulfate or ferric chloride under various testing conditions.
    CHANG SL; STEVENSON RE; BRYANT AR; WOODWARD RL; KABLER PW
    Am J Public Health Nations Health; 1958 Jan; 48(1):51-61. PubMed ID: 13487878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.